Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000423363 | SCV000529121 | uncertain significance | not provided | 2017-06-06 | criteria provided, single submitter | clinical testing | The A469T variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to ourknowledge. The A469T variant is observed in 6/66724 (0.0089%) alleles from individuals of European (non-Finnish)background, in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome VariantServer). The A469T variant is a non-conservative amino acid substitution, which is likely to impact secondaryprotein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at aposition that is conserved across species. In silico analysis predicts this variant is probably damaging to the proteinstructure/function. In summary, based on the currently available information, it is unclear whether this variant is apathogenic variant or a rare benign variant. |
Labcorp Genetics |
RCV000795287 | SCV000934739 | likely benign | Charcot-Marie-Tooth disease type 2 | 2024-09-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002461164 | SCV002755272 | uncertain significance | Inborn genetic diseases | 2023-12-18 | criteria provided, single submitter | clinical testing | Unlikely to be causative of AARS-related Charcot-Marie-Tooth disease, type 2 (AD) Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV000423363 | SCV005411350 | uncertain significance | not provided | 2024-06-25 | criteria provided, single submitter | clinical testing |